| Serial Number | 79275446 |
| Word Mark | ANOCCA |
| Filing Date | Tuesday, July 16, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, January 26, 2021 |
| Registration Number | 6253450 |
| Registration Date | Tuesday, January 26, 2021 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, November 10, 2020 |
| Description of Mark | The mark consists of the stylized wording "ANOCCA" to the left of an irregular circular shape containing curved lines and a circle. |
| Goods and Services | Immunostaining instruments for scientific purposes |
| Goods and Services | Biological preparations for veterinary and medical purposes, namely, for cell therapy; biological preparations for medical purposes in the field of ex vivo gene engineering, namely, for cell therapy; biological preparations for treatment using cellular therapeutics, namely, for cell therapy; biological preparations for treatment using cellular therapy; biological preparations for medical use for cell therapy; biological preparations for treatment of diseases using cells, namely, for cell therapy; biological preparations for medical purposes for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; biological preparations for treatment of cancer; biological tissue cultures for medical purposes; cellular function activating agents for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic preparations and substances for veterinary and medical purposes; diagnostic preparation for medical use; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical purposes; immunoassay reagents for medical use; immunomodulators; immunostimulants; in vitro diagnostic preparation for medical use; mixed biological preparations for medical purposes for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; personalized antigens for medical diagnostic use; personalized tumour antigens for medical diagnostic use; personalized tumour vaccines; personalized vaccines; pharmaceutical compositions for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; pharmaceutical compositions and substances with anti-inflammatory properties for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; pharmaceutical compositions for the prevention of autoimmune conditions; pharmaceutical compositions for the prevention of autoimmune diseases; pharmaceutical compositions for the prevention of autoimmune disorders; pharmaceutical compositions for the prevention of inflammatory conditions; pharmaceutical compositions for the prevention of inflammatory disorders; pharmaceutical compositions for the prevention of inflammatory diseases; pharmaceutical compositions for the prevention of oncological conditions; pharmaceutical compositions for the prevention of oncological disorders; pharmaceutical compositions for the prevention of oncological diseases; pharmaceutical compositions for the prevention of tumours; pharmaceutical compositions for the treatment of autoimmune conditions; pharmaceutical compositions for the treatment of autoimmune diseases; pharmaceutical compositions for the treatment of autoimmune disorders; pharmaceutical compositions for the treatment of inflammatory conditions; pharmaceutical compositions for the treatment of inflammatory disorders; pharmaceutical compositions for the treatment of inflammatory diseases; pharmaceutical compositions for the treatment of oncological conditions; pharmaceutical compositions for the treatment of oncological diseases; pharmaceutical compositions for the treatment of oncological disorders; pharmaceutical compositions for the treatment of tumours; pharmaceutical preparations for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; pharmaceutical preparations and substances for the treatment and prevention of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances with anti-inflammatory properties for the treatment of autoimmune disease, biologic drug rejection and allergy; pharmaceutical preparations for activating cellular function for the treatment of cancer, infectious disease, autoimmune disease and allergy; pharmaceutical preparations for human use in the treatment and prevention of cancer, infectious disease, allergy and autoimmune disease; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for medical purposes, namely, for the treatment of cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection; pharmaceutical preparations for prevention of tumours; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of autoimmune conditions; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of inflammatory conditions; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of oncological conditions; pharmaceutical preparations for the prevention of oncological disorders; pharmaceutical preparations for the prevention of oncological diseases; pharmaceutical preparations for the treatment of autoimmune conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of inflammatory conditions; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of oncological conditions; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations for the treatment of oncological disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of digestive system disorders; pharmaceutical preparations for treatment of tumours; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; preparations for detecting genetic predispositions for medical purposes; prophylactic vaccines; reagents for use in medical genetic testing; medical diagnostic reagents in the nature of tumour antigens for use in the detection of cancer; tumour vaccines; vaccines; vaccines for human use; viral vaccines |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Biochemicals, namely, for in vitro genetic engineering use; biochemicals, namely, for ex vivo genetic engineering use; biochemicals, namely, precursors for in vitro genetic engineering use; biochemicals, namely, precursors for ex vivo genetic engineering use; biological preparations for use in cell cultures other than for medical or veterinary use; biological preparations, namely, for in vitro genetic engineering use; biological preparations, for ex vivo genetic engineering use; biological preparations, namely, precursors for in vitro genetic engineering use; biological preparations, namely, precursors for ex vivo genetic engineering use; biological preparations for use in industry and science in the diagnosis of disease and manufacture of cell-based therapies and vaccines; biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparations other than for medical use; biological preparations for use in industry and science; chemical reagents for molecular biology, other than for medical or veterinary use; chemical reagents for use in biotechnology, other than for medical or veterinary use; chemical reagents, namely, for in vitro genetic engineering use; chemical reagents, for ex vivo genetic engineering use; chemical reagents, namely, precursors for in vitro genetic engineering use; chemical reagents, namely, precursors for ex vivo genetic engineering use; diagnostic preparations, other than for medical or veterinary purposes; diagnostic preparations, namely, for in vitro genetic engineering use; diagnostic preparations, for ex vivo genetic engineering use; diagnostic preparations, namely, precursors for in vitro genetic engineering use; diagnostic preparations, namely, precursors for ex vivo genetic engineering use; immunoassay reagents, other than for medical use; immunoassay reagents, namely, for in vitro genetic engineering use; immunoassay reagents, for ex vivo genetic engineering use; immunoassay reagents, namely, precursors for in vitro genetic engineering use; immunoassay reagents, namely, precursors for ex vivo genetic engineering use; immunoassays based on polypeptides for determining immunological profile, other than for medical use; reagents for use in immunoserology for non-medical purposes; reagents, namely, for in vitro genetic engineering use; reagents, namely, for ex vivo genetic engineering use; reagents, namely, precursors for in vitro genetic engineering use; reagents, namely, precursors for ex vivo genetic engineering use |
| Translation of Words in Mark | The wording "ANOCCA" has no meaning in a foreign language. |
| Goods and Services | Blood bank services; medical clinic services; therapy services, namely, T-cell therapy; blood banks; medical clinics; medical clinic services; medical health clinic services; medical and health care clinics; providing personalized therapy for treating cancer; providing personalized medical and health care services; provision of medical services; medical testing services relating to the diagnosis and treatment of disease; medical diagnostic testing services relating to ex vivo gene engineering, namely, cell therapy; medical diagnostic testing services relating to cellular therapeutics, namely, cell therapy; medical diagnostic testing services relating to cell therapy; medical diagnostic testing services relating to cellular therapy; medical diagnostic testing services relating to treatment of diseases using cells; medical analysis services relating to the collection, treatment and processing of human blood for diagnostic and treatment purposes; medical services for the treatment of cancer, autoimmune disease or inflammatory disease; medical services for the treatment of conditions of the human body; medical screening services relating to oncological disease, autoimmune disease or inflammatory disease; medical care and medical analysis services relating to patient treatment for diagnostic and treatment purposes; medical diagnostic testing, monitoring and reporting services; medical health assessment services; medical laboratory services for the analysis of samples taken from patients, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical laboratory services for the analysis of blood samples taken from patients for diagnostic and treatment purposes; medical analysis services for diagnostic and treatment purposes; medical analysis services relating to the treatment of persons; medical analysis services relating to the treatment of patients; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical and health services, namely, medical analysis services relating to DNA, genetics and genetic testing for medical diagnostic and treatment purposes; medical and health care services; medical services in the field of oncology; genetic testing for medical purposes |
| Goods and Services | Apparatus for the diagnosis of autoimmune conditions; medical apparatus for treatment using ex vivo genetic engineering, namely, apparatus for use in cell therapy; medical apparatus for cellular therapeutics; medical apparatus for cell therapy; medical apparatus for cellular therapy; apparatus for treatment of diseases using cells, namely, apparatus for use in cell therapy; apparatus for the diagnosis of autoimmune diseases; apparatus for the diagnosis of autoimmune disorders; apparatus for the diagnosis of inflammatory conditions; apparatus for the diagnosis of inflammatory diseases; apparatus for the diagnosis of inflammatory disorders; apparatus for the diagnosis of oncological conditions; apparatus for the diagnosis of oncological diseases; apparatus for the diagnosis of oncological disorders; apparatus for tumour diagnosis; diagnostic apparatus for medical purposes for testing antigen targets in cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection, and in providing targeting immune receptors for antigen targets in said diseases; diagnostic imaging apparatus for medical use; diagnostic instruments for medical use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing; medical diagnostic testing apparatus for use in immunoassay procedure; genetic testing apparatus for medical purposes |
| Goods and Services | Analysis in the field of molecular biology; analysis of human serum for medical research; analysis of human tissues for medical research; biochemical research and analysis; biochemical research in the field of ex vivo gene engineering; biochemical research in the field of cellular therapeutics; biochemical research in the field of cell therapy; biochemical research in the field of cellular therapy; biochemical research in the field of treatment of diseases using cells; biological laboratory services for scientific research purposes; biological research; biological research and analysis; biological research laboratory services; biological research services; biological research, clinical research and medical research; biomedical research services; biotechnology research; blood analysis services for scientific research purposes; cell separation research services; clinical trials for others; conducting clinical trials for others; conducting clinical trials for others for pharmaceutical products; conducting clinical trials for others in the field of autoimmune disease therapy; conducting clinical trials for others in the field of cancer therapy; conducting clinical trials for others in the field of gene therapy; contract research services, namely, medical, pharmaceutical, and scientific research for others relating to molecular sciences; DNA screening for scientific research purposes; genetic engineering services, namely, scientific research in the field of genetics and genetic engineering; genetic engineering services, namely, scientific research in the field of genetics and genetic engineering relating to plants; genetic research; genetic testing for scientific research purposes; scientific laboratory services; laboratory research in the field of immunobiology; laboratory research in the field of gene expression; laboratory research services relating to pharmaceuticals; scientific laboratory testing services; laboratory services relating to the production of monoclonal antibodies; medical laboratory testing services; medical and pharmacological research services; medical laboratory services; medical research; medical research laboratory services; medical research services; pharmaceutical research and development; pharmaceutical research and development services; pharmaceutical research services; scientific laboratory services, namely, preparation of biological samples for analysis in research laboratories; scientific laboratory services, namely, preparation of biological samples for research purposes; scientific laboratory services, namely, preparation of biological samples for testing and analysis in research laboratories; product research and development; research and development for the pharmaceutical industry; research and development in the field of biotechnology; research and development in the field of diagnostic preparations; research and development in the field of immunology; research and development in the pharmaceutical and biotechnology fields; research and development of new products; research and development of new products for third parties in the field of autoimmunity, cancer and rheumatoid heart disease; research and development of vaccines and medicines; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of immunology; research and development services in the field of microorganisms and cells; research and development services relating to vaccines; research in the field of autoimmune disease; research in the field of gene therapy; research in the field of genetic engineering; research in the field of inflammatory diseases; research in the field of oncology; research laboratories in the field of immunobiology; research laboratory services in the field of immunobiology; research of pharmaceuticals; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to medicine; research relating to molecular biology; research relating to pharmaceuticals; research relating to science, namely, scientific research; scientific investigations for medical purposes; scientific laboratory services; scientific research; scientific research and analysis in the field of immunobiology; scientific research and development; scientific research for medical purposes in the field of cancer, autoimmune diseases, infectious diseases, inflammatory diseases and allergy; scientific research for medical purposes in the area of cancerous disease; scientific research in the field of genetics and genetic engineering; scientific research relating to biology; scientific research relating to cellular therapeutics; scientific research relating to genetics; scientific research relating to immunotherapeutics; scientific research relating to prophylactic vaccines; scientific research services; scientific services, namely, scientific consulting and research services relating to the isolation and cultivation of human tissue and cells; scientific testing services in the field of identifying antigen targets in cancer, infectious disease, allergy, autoimmune disease and biologic drug rejection, and in providing targeting immune receptors for antigen targets in said diseases |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus. |
| US Class Codes | 021, 023, 026, 036, 038 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 009 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 8, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Anocca AB |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | SE-371 33 Karlskrona SE |
| Party Name | Anocca AB |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | SE-371 33 Karlskrona SE |
| Party Name | Anocca AB |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | SE-371 33 Karlskrona SE |
| Event Date | Event Description |
| Saturday, June 11, 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| Thursday, October 28, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Sunday, May 23, 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, April 29, 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, April 29, 2021 | FINAL DISPOSITION PROCESSED |
| Monday, April 26, 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, January 26, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Saturday, December 12, 2020 | NOTIFICATION PROCESSED BY IB |
| Wednesday, November 25, 2020 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, November 10, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 10, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 21, 2020 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, October 21, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, October 5, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, October 5, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Monday, October 5, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, October 5, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Monday, October 5, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, September 29, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, September 29, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, September 17, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 17, 2020 | NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED |
| Thursday, September 17, 2020 | NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED |
| Thursday, September 17, 2020 | REPORT UNRESPONSIVE AMENDMENT - COMPLETED |
| Wednesday, August 26, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, August 26, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, August 25, 2020 | ASSIGNED TO LIE |
| Wednesday, August 5, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, February 22, 2020 | REFUSAL PROCESSED BY IB |
| Thursday, February 6, 2020 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, February 6, 2020 | REFUSAL PROCESSED BY MPU |
| Tuesday, January 14, 2020 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, January 14, 2020 | APPLICATION FILING RECEIPT MAILED |
| Monday, January 13, 2020 | NON-FINAL ACTION WRITTEN |
| Thursday, January 9, 2020 | ASSIGNED TO EXAMINER |
| Wednesday, January 8, 2020 | ASSIGNED TO EXAMINER |
| Wednesday, January 8, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, January 2, 2020 | SN ASSIGNED FOR SECT 66A APPL FROM IB |